131 related articles for article (PubMed ID: 11844840)
1. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Bleiberg H; Di Leo A
J Clin Oncol; 2002 Feb; 20(4):1145-6. PubMed ID: 11844840
[No Abstract] [Full Text] [Related]
2. [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Motomura S
Nihon Rinsho; 2003 Sep; 61 Suppl 7():360-3. PubMed ID: 14574913
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
4. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Alimonti A; Satta F; Pavese I; Burattini E; Zoffoli V; Vecchione A
Ann Oncol; 2003 May; 14(5):805-6. PubMed ID: 12702539
[No Abstract] [Full Text] [Related]
5. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
7. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Pestalozzi BC
N Engl J Med; 2001 Jan; 344(4):306; author reply 306-7. PubMed ID: 11191662
[No Abstract] [Full Text] [Related]
9. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Klautke G; Fietkau R
Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194
[No Abstract] [Full Text] [Related]
10. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Hwang JJ
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer.
Mishima H; Ikenaga M; Ishida H; Iwamoto S; Morimoto T; Narahara H; Kato T; Tsujie M; Kitai T; Fukunaga M; Nakanishi M; Tsujinaka T; Furukawa H; Taguchi T;
Anticancer Res; 2007; 27(2):1003-8. PubMed ID: 17465234
[TBL] [Abstract][Full Text] [Related]
13. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Allegra C; George T; Yothers G
J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
[No Abstract] [Full Text] [Related]
14. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Erlichman C; Goldberg RM; O'Connell MJ
N Engl J Med; 2001 Jan; 344(4):305; author reply 306-7. PubMed ID: 11191661
[No Abstract] [Full Text] [Related]
15. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
[No Abstract] [Full Text] [Related]
16. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
[No Abstract] [Full Text] [Related]
17. Toxicity of irinotecan in patients with colorectal cancer.
Van Cutsem E; Douillard JY; Köhne CH
N Engl J Med; 2001 Nov; 345(18):1351-2. PubMed ID: 11794165
[No Abstract] [Full Text] [Related]
18. A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Gennatas C; Papaxoinis G; Michalaki V; Mouratidou D; Andreadis C; Tsavaris N; Pafiti A
J Chemother; 2006 Oct; 18(5):538-44. PubMed ID: 17127232
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond fluorouracil for colorectal cancer.
Mayer RJ
N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
[No Abstract] [Full Text] [Related]
20. Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Chico IM; Pazdur R
Clin Colorectal Cancer; 2002 May; 2(1):11-2. PubMed ID: 12453329
[No Abstract] [Full Text] [Related]
[Next] [New Search]